Table 2.

Patient-reported outcome measures between baseline and Week 2.

	Fan groupa		Control groupa		Treatment effectb	p value
	Baseline	Week 2	Baseline	Week 2
Dyspnoea-12	16.1 ± 2.2	13.4 ± 2.3	13.3 ± 2.2	12.8 ± 2.2	− 2.2 (− 6.4, 1.9)	0.29
K-BILD Breathlessness & Activities	29.2 ± 3.9	32.2 ± 3.9	32.5 ± 3.7	37.0 ± 3.7	− 1.5 (− 8.9, 5.9)	0.69
K-BILD Chest Symptoms	47.0 ± 5.2	56.1 ± 5.4	59.6 ± 5.0	58.8 ± 5.2	10 (− 5.1, 25.1)	0.19
K-BILD Psychological Symptoms	51.7 ± 4.2	53.4 ± 4.2	56.9 ± 4.1	57.5 ± 4.1	1.1 (− 4.1, 6.3)	0.40
K-BILD Total	48.0 ± 2.5	50.3 ± 2.5	52.3 ± 2.4	54.0 ± 2.4	0.7 (− 3.3, 4.7)	0.33
Self-efficacyc	5.4 ± 0.6	5.7 ± 0.7	5.5 ± 0.6	5.7 ± 0.6	0.07 (− 1.9, 2.0)	0.94
Activities of daily livingd	14.4 ± 0.9	14.6 ± 1.0	15.1 ± 0.9	16.9 ± 0.9	− 2.5 (− 4.8, 0.3)	0.08
Life-spacee	58.6 ± 6.3	58.0 ± 6.4	66.6 ± 6.1	63.7 ± 6.1	2.4 (− 10.4, 15.2)	0.72

Measured using: ^cSelf-efficacy for Managing Chronic Disease 6-item Scale; ^dManchester Respiratory Activities of Daily Living Questionnaire; ^eUniversity of Alabama at Birmingham Study of Aging Life-Space Assessment.

Data are expressed as ^amean ± standard error or ^bmean difference (95% confidence interval). P values are between group comparison for mean difference.

K-BILD King’s Brief Interstitial Lung Disease.